Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$65.27 USD
-1.81 (-2.70%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $65.09 -0.18 (-0.28%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
Average Brokerage Rating
Current ABR | 2.24 |
ABR (Last week) | 2.24 |
# of Recs in ABR | 25 |
Average Target Price | $84.18 |
LT Growth Rate | 13.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -1.49 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 11 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 14 | 14 | 11 | 11 | 9 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.24 | 2.24 | 2.14 | 2.14 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
2/22/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/12/2024 | Needham & Company | Joseph R Stringer | Not Available | Hold |
2/7/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
2/7/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
1/8/2024 | Maxim Group | Michael Okunewitch | Strong Buy | Strong Buy |
11/9/2023 | Not Identified | Not Identified | Hold | Hold |
11/8/2023 | Not Identified | Not Identified | Not Available | Hold |
11/7/2023 | Not Identified | Not Identified | Hold | Hold |
10/11/2023 | SVB Securities | Daina M Graybosch | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.